Early Alterations in Neutrophil Activation Are Associated with Outcome in Acute Lung Injury

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 11, 2003, Pages 1567-1574

  Yang, Kuang Yao ^b   Arcaroli, John J ^b   Abraham, Edward ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

Cellular activation; Lung; Neutrophils; Signal transduction; Transcription factors

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; SYNAPTOPHYSIN; AKT1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HUMAN; INTUBATION; LEUKOCYTE ACTIVATION; LUNG INJURY; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL; TRANSCRIPTION REGULATION; VENTILATOR; ADULT RESPIRATORY DISTRESS SYNDROME; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NEUTROPHIL ACTIVATION; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RESPIRATORY DISTRESS SYNDROME, ADULT; SIGNAL TRANSDUCTION;

EID: 0038132126     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200207-664OC     Document Type: Article

References (40)

1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824.
2. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997;155:1187-1205.
3. Ware LB, Matthay MA. Medical progress: the acute respiratory distress syndrome. N Engl J Med 2000;342:1334-1339.
4. Abraham E, Carmody A, Shenkar R, Arcaroli J. Neutrophils as early immunologic effectors in hemorrhage or endotoxemia induced acute lung injury. Am J Physiol 2000;279:L1137-L1146.
5. Chignard M, Balloy V. Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. Am J Physiol 2000;279:L1083-L1090.
6. Azoulay E, Darmon M, Delclaux C, Fieux F, Bornstain C, Moreau D, Attalah H, Le Gall JR, Schlemmer B. Deterioration of precious acute lung injury during neutropenia recovery. Crit Care Med 2002;30:781-786.
7. Rinaldo JE, Borovetz H. Deterioration of oxygenation and abnormal lung microvascular permeability during resolution of leukopenia in patients with diffuse lung injury. Am Rev Respir Dis 1985;131:579-583.
8. Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, Grant IS, Pollok AJ, Haslett C. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993;341:643-647.
9. Pugin J, Ricou B, Steinberg KP, Suter PM, Martin TR. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med 1996;153: 1850-1856.
10. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest 1995;108:1303-1314.
11. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109:S81-S96.
12. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16: 225-260.
13. Moine P, McIntyre R, Schwartz MD, Kaneko D, Shenkar R, Le Tulzo Y, Moore EE, Abraham E. NF-κB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock 2000;13:85-91.
14. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation. J Immunol 1996;157:1630-1637.
15. Yum HK, Arcaroli J, Kupfner J, Shenkar R, Penninger JM, Sasaki T, Yang KY, Park JS, Abraham E. Involvement of PI3-K in neutrophil activation and the development of acute lung injury. J Immunol 2001; 167:6601-6608.
16. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez JJ, Montiel C. Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000; 68:1942-1945.
17. Bohrer H, Qiu F, Zimmerman T, Zhang Y, Jilmer T, Manner D, Bottinger BW, Stern DM, Waldherr R, Saeger HD, et al. Role of NF-κB in the mortality of sepsis. J Clin Invest 1997;100:972-985.
18. Nick JA, Avdi NJ, Young SK, Lehman LA, McDonald PP, Frasch SC, Billstrom MA, Henson PM, Johnson GL, Worthen GS. Selective activation and functional significance of p38α mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J Clin Invest 1999; 103:851-858.
19. The ARDS Network. A trial of traditional tidal volume versus lower tidal volume ventilation in acute lung injury and acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
20. Haslett C, Guthrie LA, Kopaniak MM, Johnston RB, Henson PM. Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol 1985;119: 101-110.
21. Nijhuis E, Lammers JJ, Koenderman L, Coffer PJ. Src kinases regulate PKB activation and modulate cytokine and chemoattractant-controlled neutrophil functioning. J Leukoc Biol 2002;71:115-124.
22. Abraham E, Arcaroli J, Shenkar R. Activation of ERK1/ERK2, NF-κB, and CREB in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. J Immunol 2001;166:522-530.
23. Abraham E, Bursten S, Shenkar R, Allbee J, Tuder R, Woodson P, Guidot DM, Rice G, Singer JW, Repine JE. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury following hemorrhage. J Exp Med 1995;181:569-575.
24. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-κB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 1998;273:21178-21186.
25. Kunsch C, Rosen CA. NF-κB subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993;13:6137-6146.
26. Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G, et al. Characterization of a functional NF-κB site in the human interleukin 1β promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993;13:6231-6240.
27. Parsey MV, Tuder R, Abraham E. Neutrophils are major contributors to intraparenchymal lung IL-1β expression after hemorrhage and endotoxemia. J Immunol 1998;160:1007-1013.
28. Adib-Conquy M, Adrie C, Moine P, Asehnoune K, Fitting C, Pinsky MR, Dhainaut JF, Cavaillon JM. NF-κB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med 2000;162:1877-1883.
29. McCall CE, Grosso-Wilmoth LM, LaRue K, Guzman RN, Cousart SL. Tolerance to endotoxin-induced expression of the interleukin-1β gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 1993;91:853-861.
30. West MA, Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002; 30:S64-S73.
31. Park WY, Frevert CW, Wong VA, Martin TR. High and low inflammatory response phenotypes in 101 normal human subjects. Chest 2002;121: 87S-88S.
32. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumor necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-85.
33. Romashkova JA, Makarov SS. NF-κB is a target of Akt in anti-apoptotic PDGF signalling. Nature 1999;401:86-90.
34. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the IκB kinase α and β subunits in liberating nuclear factor κB (NF-κB) from IκB and in phosphorylating the p65 subunit of NF-κB. J Biol Chem 2002;277:3863-3869.
35. Nick JA, Young SK, Brown KK, Avdi NJ, Arndt PG, Suratt BT, Janes MS, Henson PM, Worthen GS. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol 2000; 164:2151-2159.
36. Nick JA, Young SK, Arndt PG, Lieber JG, Suratt BT, Poch KR, Avdi NJ, Malcolm KC, Taube C, Henson PM, et al. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J Immunol 2002;169:5260-5269.
37. Arcaroli J, Yum H-K, Park JS, Yang K-Y, Abraham E. Role of p38 MAP kinase in the development of acute lung injury. Clin Immunol 2001; 101:211-219.
38. Kupfner JG, Arcaroli J, Yum H-K, Nadler SG, Abraham E. Role of NF-κB in endotoxemia induced alterations of lung neutrophil apoptosis. J Immunol 2001;167:7044-7051.
39. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999;96:9136-9141.
40. Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923.